Aurora Cannabis

Curaleaf Keeps Aurora Bid Open, Attacks Organigram Alternative Deal

Image
Curaleaf Keeps Aurora Bid Open, Attacks Organigram Alternative Deal

Stamford -- Curaleaf Holdings says its enhanced premium offer of October 6, 2026 for all outstanding Aurora Cannabis common shares remains open, after Aurora announced an alternative transaction with Organigram Global.

Curaleaf argues its offer delivers better value, a combined business with a stronger capital markets profile, greater certainty and speed to close, and larger anticipated synergies. The offer is made under an Offer to Purchase and Circular dated August 18, 2026, amended on October 6, 2026. Curaleaf has filed a Form F-80 registration statement and a Schedule 14D-1F tender offer statement with the U.S. SEC.

Curaleaf Q3 Revenue Hits Record $352.7M as International Jumps 28%

Image
Curaleaf Q3 Revenue Hits Record $352.7M as International Jumps 28%

STAMFORD – November 03, 2026 -- Curaleaf Holdings reported record third-quarter net revenue of $352.7 million, up 10.9% from $317.9 million a year earlier, as its international segment grew 28% and its domestic business grew 8%. Sequentially, revenue rose 3.6% from $340.1 million in the second quarter of 2026.

International sales reach $59 million as U.S. growth extends to a third quarter

International revenue totaled $59 million in the quarter. The U.S. business has now posted three consecutive quarters of year-over-year growth. Chairman and CEO Boris Jordan said cannabis demand stayed resilient despite mounting pressure on consumers.

Curaleaf secured its first two registrations for standardized cannabis preparations in Spain during the quarter.

Aurora Board Rejects Revised Curaleaf Bid, Opens Strategic Review

Image
Aurora Board Rejects Revised Curaleaf Bid, Opens Strategic Review

Edmonton – October 15, 2026 -- Aurora Cannabis' board unanimously recommended that shareholders reject Curaleaf Holdings' revised hostile offer, which remains open until October 15, 2026, and said its special committee is actively exploring alternatives, including a deal with one or more third parties.

The recommendation, made on the unanimous advice of a special committee of independent directors, responds to the Notice of Variation, Change and Extension that Curaleaf filed on October 15, 2026. Aurora's financial advisor delivered an updated opinion concluding that the revised consideration is inadequate, from a financial point of view, to Aurora shareholders.

Board says revised offer shifts risk and cost onto Aurora shareholders

Aurora argues that the increase in consideration consists principally of Curaleaf shares at an inflated valuation. Aurora shareholders would therefore stay fully exposed to any decline in the Curaleaf share price.

Curaleaf Rebuts Aurora Cannabis Claims, Defends Takeover Premium

Stamford, Conn. – – September 12, 2026 -- Curaleaf Holdings, Inc. released a fact sheet countering what it called inaccurate statements by Aurora Cannabis Inc. regarding Curaleaf's proposal to acquire the company, arguing its offer represents one of the highest premiums in a decade of Canadian M&A.

Curaleaf says its bid carries a 110% premium once Aurora's cash is excluded

Curaleaf's headline offer reflects a 45% premium, which the company says ranks among the higher Canadian M&A premiums of the past ten years. Stripping out cash on Aurora's balance sheet, Curaleaf calculates the effective premium at 110%. Curaleaf noted Aurora has continued issuing shares through an At-the-Market program at prices below the value implied by the offer, even after the bid was made public.